Most digital pathology platforms stop at the image. Lumea brings molecular and ancillary testing into the viewer itself, so the send-outs your clinicians trust are ordered and tracked from inside the case, without a separate portal or LIS.
Ordering Should Live Where You Already Are
Molecular test ordering is becoming a standard feature, and a growing number of platforms now embed it into the LIS.
Lumea takes a different path by embedding ordering in the viewer where the pathologist is already reading the case. This means no more toggling between programs, no second login, no portal to remember, and no duplicate uploads or re-entry.
That distinction does more than save clicks. It keeps the entire diagnostic picture in one place at the moment the decision is being made, so ordering a send-out becomes a natural part of reading the case rather than a separate task handed off to another system.
Fewer Windows Means Lower Risk
When a single patient’s case is split across multiple systems, screens, and logins, every additional window is one more place for something to be transposed, mismatched, or missed. Consolidating ordering, slides, patient identity, and reporting into one connected workspace removes those manual checkpoints and the potential errors that hide in them.
For pathologists, that means patient safety is built into the workflow rather than guarded by vigilance alone. For labs, it means fewer of the quality and liability exposures that come with fragmented, hand-off-heavy processes.
Better Specimens Before Anyone Clicks Order
Quantity-not-sufficient (QNS) rates as high as 23% have been documented in metastatic prostate cancer samples, and each one is a delayed answer and increased costs for a patient. Software cannot solve that, because the problem starts at collection.
The Lumea BxBoard®’s improved fixation method prevents autolysis and its lanes minimize tissue distortion and fragmentation. The result is a 2.1x reduction in test cancellations due to QNS and RNA degradation, which means more patients who actually receive the result their care depends on.
The Value to Your Practice
| Feature | The Lumea Advantage |
| Ordering in the Viewer | Order molecular tests from inside the case in the IMS, not a separate LIS or portal |
| Built-In Safety | Fewer open windows per patient means fewer chances for case data to be mixed up |
| Better Specimen Quality | BxBoard better preserves tissue, so more samples run the first time |
| 45-62% Faster Turnaround | Reduce delays caused by disconnected workflows and manual hand-offs |
| Operational Efficiency | Eliminate redundant systems, portals, and administrative steps |
| Diagnostic Continuity | Keep slides, molecular results, reporting, and case data connected |
| Open Ecosystem | Choose the molecular partners and tests that fit your practice and add new ones without having to change platforms |
Not an IMS With Extras. Not an LIS With Add-Ons.
Lumea is a full diagnostic suite, built around how pathologists actually work. Digital pathology, molecular testing, workflow management, and reporting live in one connected experience, with ordering, slides, and results inherently linked rather than stitched together after the fact. One platform. One workflow. Better diagnostic coordination from biopsy to final report.
And when using the whole Lumea system for ordering and better specimens, patient cases move from biopsy to final report with less friction and fewer dead ends.
